E. Vercauteren

发表

Comparison of Direct Plating and Broth Enrichment Culture for the Detection of Intestinal Colonization by Glycopeptide-Resistant Enterococci among Hospitalized Patients

H. Goossens, M. Ieven, F. Van Laer, 1999, Journal of Clinical Microbiology.

Survey of enterococcal susceptibility patterns in Belgium

H. Goossens, P. Vandamme, B. Pot, 1996, Journal of clinical microbiology.

Is there any need for a TAFI(a) inhibitor as thrombolytic drug?

A. Gils, E. Vercauteren, 2012, Thrombosis research.

Thrombin Activatable Fibrinolysis Inhibitor: A Putative Target to Enhance Fibrinolysis

A. Gils, P. Declerck, E. Vercauteren, 2013, Seminars in Thrombosis & Hemostasis.

The hyperfibrinolytic state of mice with combined thrombin‐activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor‐1 gene deficiency is critically dependent on TAFI deficiency

A. Gils, H. Lijnen, M. Peeters, 2012, Journal of thrombosis and haemostasis : JTH.

Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model.

A. Gils, P. Declerck, M. Hoylaerts, 2011, Blood.

Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital

H. Goossens, M. Ieven, M. Ieven, 1997, Journal of clinical microbiology.

Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue

P. Sloan, T. Steiniche, A. Long, 2017, Journal of Clinical Pathology.

Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms

A. Gils, P. Declerck, E. Vercauteren, 2011, Thrombosis and Haemostasis.